OXU 005
Alternative Names: OXU-005Latest Information Update: 26 Aug 2022
At a glance
- Originator Oxular
- Class Eye disorder therapies; Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Age-related macular degeneration; Diabetic retinopathy
Most Recent Events
- 20 Jul 2022 Oxular plans phase II trial for Diabetic retinopathy in 2025 (Oxular pipeline, August 2022)
- 20 Jul 2022 Oxular plans to submit IND application for Diabetic retinopathy in 2024 (Oxular pipeline, July 2022)
- 04 Mar 2021 Preclinical trials in Age-related macular degeneration in United Kingdom (Ophthalmic) prior to March 2021